Canada markets open in 4 hours 2 minutes

Aclarion, Inc. (ACON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6497-0.0403 (-5.84%)
At close: 03:59PM EST
0.7021 +0.05 (+8.07%)
After hours: 05:43PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.6900
Open0.6900
Bid0.0000 x 1800
Ask0.0000 x 4000
Day's Range0.6000 - 0.6995
52 Week Range0.3800 - 4.0500
Volume20,459
Avg. Volume41,531
Market Cap5.082M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.1200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

    Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and i

  • Newsfile

    Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event

    Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26th.Event: Q1 Investor SummitDate: January 26th, 2023Presentation: January 26t

  • GlobeNewswire

    Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor

    Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Dr. Christopher Ames, Director of Spinal Deformity and Spine Tumor Surgery and Co-Director of the Combined High Risk Spine Service, the Neurospinal Disorders Pro